Tag: TOBA II BTK
Philips announces positive three-year clinical research results from its TOBA II...
Royal Philips today announced the latest results from the Tack optimised balloon angioplasty (TOBA) II below-the-knee (BTK) clinical trial, demonstrating that the Philips endovascular...
Philips announces positive two-year data from TOBA II BTK clinical trial
Royal Philips recently announced positive two-year results from the TOBA (Tack optimised balloon angioplasty) II below-the-knee (BTK) clinical trial.
The data show the Philips...
Intact Vascular announces positive one-year data from TOBA II BTK clinical...
Intact Vascular announced the positive one-year results from its Tack optimised balloon angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA)...
First US commercial use of Tack Endovascular System (4F) in BTK...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints...
It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...
TOBA II BTK clinical trial completes enrolment
The Tack Optimised Balloon Angioplasty II below-the-knee (TOBA II BTK) clinical trial has successfully completed enrolment, ahead of schedule. This study, sponsored by Intact...
US FDA approves TOBA II BTK pivotal IDE clinical study
The US Food and Drug Administration (FDA) has granted staged approval for Intact Vascular’s investigational device exemption (IDE) application to begin its TOBA II...
